T-cell adult acute lymphocytic leukemia
diseaseOn this page
Also known as adult acute lymphoblastic leukaemia of T celladult acute lymphoblastic leukemia of T celladult precursor T lymphoblastic leukaemiaadult precursor T-lymphoblastic leukaemiaadult precursor T-lymphoblastic leukemiaadult T acute lymphoblastic leukaemiaadult T acute lymphoblastic leukemiaadult T-cell acute lymphoblastic leukaemiaadult T-cell acute lymphoblastic leukemiaT cell adult acute lymphoblastic leukaemiaT cell adult acute lymphoblastic leukemiaT cell adult acute lymphocytic leukaemiaT cell adult acute lymphocytic leukemiaT cell adult ALLT-cell adult ALL
Summary
T-cell adult acute lymphocytic leukemia (MONDO:0003539) is a cancer and 16 clinical trials. Top therapeutic interventions include mercaptopurine anhydrous, daunorubicin, and asparaginase. A subtype of adult acute lymphoblastic leukemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 16
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | T-cell adult acute lymphocytic leukemia |
| Mondo ID | MONDO:0003539 |
| EFO | EFO:1001936 |
| DOID | DOID:5602 |
| NCIT | C9142 |
| UMLS | C0279592 |
| MedGen | 79009 |
| GARD | 0023554 |
| Is cancer (heuristic) | yes |
Also known as: adult acute lymphoblastic leukaemia of T cell · adult acute lymphoblastic leukemia of T cell · adult precursor T lymphoblastic leukaemia · adult precursor T-lymphoblastic leukaemia · adult precursor T-lymphoblastic leukemia · adult T acute lymphoblastic leukaemia · adult T acute lymphoblastic leukemia · adult T-cell acute lymphoblastic leukaemia · adult T-cell acute lymphoblastic leukemia · T cell adult acute lymphoblastic leukaemia · T cell adult acute lymphoblastic leukemia · T cell adult acute lymphocytic leukaemia · T cell adult acute lymphocytic leukemia · T cell adult ALL · T-cell adult ALL
Data availability: 57 cell lines.
Disease family
This is a subtype of adult acute lymphoblastic leukemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › precursor lymphoblastic lymphoma/leukemia › acute lymphoblastic leukemia › adult acute lymphoblastic leukemia › T-cell adult acute lymphocytic leukemia
Related subtypes (1): B-cell adult acute lymphocytic leukemia
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 16.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 7 |
| PHASE2 | 5 |
| PHASE1/PHASE2 | 3 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02112916 | PHASE3 | ACTIVE_NOT_RECRUITING | Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma |
| NCT00792948 | PHASE2 | ACTIVE_NOT_RECRUITING | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia |
| NCT00052520 | PHASE1/PHASE2 | COMPLETED | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation |
| NCT00061945 | PHASE1/PHASE2 | COMPLETED | Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia |
| NCT00873093 | PHASE2 | COMPLETED | Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma |
| NCT00918333 | PHASE1/PHASE2 | COMPLETED | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma |
| NCT01093586 | PHASE2 | COMPLETED | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
| NCT01258998 | PHASE2 | COMPLETED | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma |
| NCT02619630 | PHASE2 | UNKNOWN | Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old) |
| NCT00301938 | PHASE1 | COMPLETED | 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes |
| NCT00608361 | PHASE1 | COMPLETED | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery |
| NCT01139970 | PHASE1 | COMPLETED | Veliparib and Temozolomide in Treating Patients With Acute Leukemia |
| NCT01567709 | PHASE1 | COMPLETED | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma |
| NCT01588015 | PHASE1 | COMPLETED | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant |
| NCT02168140 | PHASE1 | COMPLETED | CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma |
| NCT02228772 | PHASE1 | COMPLETED | Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| MERCAPTOPURINE ANHYDROUS | 4 | 6 |
| DAUNORUBICIN | 4 | 3 |
| ASPARAGINASE | 4 | 2 |
| DASATINIB ANHYDROUS | 4 | 2 |
| PEGASPARGASE | 4 | 2 |
| VINCRISTINE | 4 | 2 |
| ACYCLOVIR | 4 | 1 |
| ALEMTUZUMAB | 4 | 1 |
| ALLOPURINOL | 4 | 1 |
| BENDAMUSTINE HYDROCHLORIDE | 4 | 1 |
| BORTEZOMIB | 4 | 1 |
| ETOPOSIDE PHOSPHATE | 4 | 1 |
| HYDROCORTISONE SODIUM SUCCINATE | 4 | 1 |
| IFOSFAMIDE | 4 | 1 |
| IMATINIB | 4 | 1 |
| NELARABINE | 4 | 1 |
| PANOBINOSTAT | 4 | 1 |
| THIOGUANINE | 4 | 1 |
| VELIPARIB | 3 | 2 |
| ALISERTIB | 3 | 1 |
| CPI 613 | 3 | 1 |
| PERIFOSINE | 3 | 1 |
| UCN-01 | 2 | 1 |
| CHEMBL4583196 | 0 | 1 |
| CHEMBL344227 | 0 | 1 |
| CHEMBL406352 | 0 | 1 |
| CHEMBL1236539 | 0 | 1 |